caspofungin
Trade name: cancidas
Small moleculeapprovedFast Track FDA
Approved
Jan 26, 2001
Caspofungin is an echinocandin antifungal drug, which is approved and is sold under the brand worldwide name cancidas. Caspofungin inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of susceptible Aspergillus species and Candida species. Beta (1,3)-D-glucan is not present in mammalian cells. Cancidas is indicated for the treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis, and pleural space infections in adult and pediatric patients. Also is indicated for the treatment of esophageal candidiasis in adult and pediatric patients and for the treatment of invasive aspergillosis in adult and pediatric patients, but has not been studied as initial therapy for invasive aspergillosis. — NCATS
Clinical trial activity
63 trials · 70 clinical orgs · 14 marketing orgs
Phase 1
2
Phase 2
45
Phase 3
21
Phase 4
10
Earliest trial started Jun 19, 2000 (NCT00005921)
Timeline
2000s
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
- Dec 30, 2016
Fresenius — NDA Secondary Org
- Sep 29, 2017
Gland Pharma Ltd — Marketing Organization
- Sep 29, 2017
Mylan — Marketing Organization
- Sep 29, 2017
PHARMOBEDIENT — Marketing Organization
- Jun 28, 2018
Hengrui Therapeutics, Inc. — Marketing Organization
- Jun 28, 2018
Sandoz — Marketing Organization
- Jun 28, 2018
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. — Marketing Organization
- Jul 2, 2018
Xellia Pharmaceuticals — Marketing Organization
- Jul 2, 2018
Novo Nordisk — Marketing Organization
- Jul 12, 2018
Cipla — Marketing Organization
2020s
- Oct 1, 2021
UBI Pharma Inc. — Marketing Organization
- Oct 1, 2021
Areva Med LLC — Marketing Organization
- Jul 18, 2025
Hangzhou Zhongmei — Marketing Organization
Indications
Approved for
Studied for
- Abdominal Injuries · Phase 2
- Aspergillosis · Phase 4
- Bacterial Infections and Mycoses · Phase 4
- Candidemia · Phase 4
- Candidiasis · Phase 4
- Candidiasis, Invasive · Phase 4
- Candidiasis, Oral · Phase 3
- Critical Illness · Phase 4
- Fever · Phase 2
- Fungemia · Phase 3
- Hematologic Neoplasms · Phase 4
- Hematopoietic Stem Cell Transplantation · Phase 2
- HIV Infections · Phase 2
- Hyperthermia · Phase 2/Phase 3
- Infections · Phase 2
- Invasive Pulmonary Aspergillosis · Phase 4
- Leukemia · Phase 3
- Leukemia, Monocytic, Acute · Phase 3
- Leukemia, Myeloid · Phase 3
- Leukemia, Myeloid, Acute · Phase 3
- Leukemia, Myelomonocytic, Acute · Phase 3
- Liver Diseases · Phase 4
- Liver Transplantation · Phase 4
- Lymphoma · Phase 3
- Mycoses · Phase 4
- Myelodysplastic Syndromes · Phase 3
- Neoplasms · Phase 3
- Neutropenia · Phase 3
- Obesity · Phase 4
- Pneumocystis Infections · Phase 1/Phase 2
- Pneumonia, Pneumocystis · Phase 4
- Pulmonary Disease, Chronic Obstructive · Phase 4
Mechanism of action
- 1,3-beta-glucan synthaseINHIBITOR
GSC1 inhibitor
- 1,3-beta-glucan synthaseINHIBITOR
1,3-beta-glucan synthase inhibitor
Approval history
- approvedPriority reviewFast trackJan 26, 2001
Chemistry & pharmacology
Loading structure…
SMILES
CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O- Mol. weight
- 1093.33 g/mol
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL499808 ↗
- WikipediaCaspofungin ↗
- NCATSF0XDI6ZL63 ↗
- ChEMBLCHEMBL5314378 ↗
- ChEMBLCHEMBL2096640 ↗
- ChEMBLCHEMBL1630575 ↗
Also known as
- 1-[(4r,5s)-5-[(2-aminoethyl)amino]-n(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-l-ornithine]-5-[(3r)-3-hydroxy-l-ornithine]-pneumocandin b0
- 1-[(4r,5s)-5-[(2-aminoethyl)amino]-n(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-l-ornithine]-5-[(3r)-3-hydroxy-l-ornithine]-pneumocandin b0
- (4r,5s)-5-((2-aminoethyl)amino)-n2-(10,12-dimethyltetradecanoyl)-4-hydroxy-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-threo-3-hydroxy-l-ornithyl-trans-3-hydroxy-l-proline cyclic (1->6) disulfide
- (4r,5s)-5-((2-aminoethyl)amino)-n(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-threo-3-hydroxy-l-ornithyl-trans-3-hydroxy-l-proline cyclic (6-1)-peptide
- (4r,5s)-5-((2-aminoethyl)amino)-n(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-threo-3-hydroxy-l-ornithyl-trans-3-hydroxy-l-proline cyclic (6-1)-peptide
- cancidas
- cancidas
- cancidas
- cancidas
- cancidas
- caspofungin
- caspofungin
- caspofungin
- caspofungin
- caspofungin
- caspofungin
- caspofungin
- caspofungin
- caspofungin
- caspofungin
- caspofungin acetate
- caspofungin acetate
- caspofungin acetate
- caspofungin acetate
- caspofungin acetate
- caspofungin acetate
- caspofungin acetate
- caspofungin acetate
- caspofungin acetate
- caspofungin diacetate
- caspofungin msd
- l 743872
- l 743,872
- l-743872
- l-743872
- l-743872
- l-743,872
- l-743,872
- l-743,872
- mk 0991
- mk-0991
- mk-0991
- mk-0991
- mk-0991
- mk-991
- pneumocandin b0, 1-((4r,5s)-5-((2-aminoethyl)amino)-n2-((10r,12s)-10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-l-ornithine)-5-((3r)-3-hydroxy-l-ornithine)-
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06892951 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2025 | Aerogen, CHU Henri Mondor, Hospital Avicenne, Institut National de la Santé Et de la Recherche Médicale, France, Sorbonne University, University Hospital, Tours, University of Angers, University of Bordeaux, University of Burgundy, University of Franche-Comté, University of Grenoble, University of Lille, University of Limoges, University of Lyon, University of Montpellier, University of Nantes, University of Nice Sophia Antipolis, University of Paris, University of Picardie Jules Verne, University of Poitiers, University of Reims, University of Rennes, University of Versailles, University of Western Brittany |
| NCT06194201 | Phase 2 | Apr 27, 2024 | Jiangsu ShengDiYa Medicine Co., Ltd. |
| NCT05421858 | Phase 3 | Feb 1, 2023 | Pfizer |
| NCT04728971 | Phase 4 | Feb 1, 2021 | Jiao Tong University |
| NCT03978559 | Phase 4 | Jun 20, 2019 | Chinese Academy of Medical Sciences |
| NCT03667690 | Phase 3 | Oct 31, 2018 | Cidara Therapeutics |
| NCT03580733 | Phase 3 | Oct 1, 2018 | University of Picardie Jules Verne |
| NCT03857399 | Phase 2 | Sep 17, 2018 | Fujian Medical University, Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT03884881 | N/A | Jan 1, 2018 | Central South University |
| NCT02895529 | Phase 4 | Nov 30, 2016 | Johnson and Johnson |
| NCT02856178 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2016 | F2G Ltd., University of Cologne |
| NCT02734862 | Phase 2 | May 1, 2016 | Cidara Therapeutics |
| NCT02603575 | N/A | Nov 1, 2015 | Capital Medical University |
| NCT02596984 | N/A | Mar 1, 2015 | Merck, University of Lyon |
| NCT02510053 | N/A | Jul 1, 2014 | Sun Yat-Sen University |
| NCT01945281 | Phase 2 | Jan 15, 2014 | Merck |
| NCT01994096 | Phase 4 | Nov 1, 2013 | University of Groningen |
| NCT01968395 | Phase 4 | Sep 1, 2013 | Erasmus University Rotterdam |
| NCT01503515 | Phase 3 | Mar 1, 2013 | National Cancer Institute (NCI) |
| NCT01288378 | Phase 3 | Mar 1, 2012 | AZ Sint-Jan, CHU Henri Mondor, European Organisation for Research and Treatment of Cancer, Katholieke Universiteit Leuven, Radboud University |
Showing 20 of 63 trials
Page 1 / 4
Organizations
Research & Development (70)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 23 | 16 | 4 | 2000 |
| National Cancer Institute (NCI) | Government | 6 | 4 | 3 | 2000 |
| Astellas | For profit | 5 | 4 | 2 | 2004 |
| Pfizer | For profit | 3 | 3 | 1 | 2009 |
| CHU Henri Mondor | Academic/Hospital | 2 | 0 | 2 | 2012 |
| Cidara Therapeutics | For profit | 2 | 2 | 2 | 2016 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 2 | 2 | 2 | 2005 |
| Gilead Sciences | For profit | 2 | 1 | 2 | 2004 |
| Jiao Tong University | Academic/Hospital | 2 | 2 | 2 | 2011 |
| Mycoses Study Group | Academic/Hospital | 2 | 1 | 2 | 2007 |
| University of Cologne | Academic/Hospital | 2 | 1 | 1 | 2006 |
| University of Lyon | Academic/Hospital | 2 | 1 | 2 | 2015 |
| University of Paris | Academic/Hospital | 2 | 1 | 2 | 2009 |
| University of Picardie Jules Verne | Academic/Hospital | 2 | 1 | 2 | 2018 |
| Aerogen | For profit | 1 | 0 | 1 | 2025 |
| AZ Sint-Jan | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Basilea Pharmaceutica | For profit | 1 | 0 | 1 | 2006 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Central South University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2019 |
70 organizations
Page 1 / 4
Marketing (16)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Areva Med LLC | For profit | MKTG | Oct 1, 2021 |
| Cipla | For profit | MKTG | Jul 12, 2018 |
| Fresenius | For profit | NDA2 | Dec 30, 2016 |
| Gland Pharma Ltd | For profit | MKTG | Sep 29, 2017 |
| Gland Pharma Ltd | For profit | MKTG | Sep 29, 2017 |
| Hangzhou Zhongmei | For profit | MKTG | Jul 18, 2025 |
| Hengrui Therapeutics, Inc. | For profit | MKTG | Jun 28, 2018 |
| Hengrui Therapeutics, Inc. | For profit | SYN | Jun 28, 2018 |
| Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. | For profit | MKTG | Jun 28, 2018 |
| Merck | For profit | NDA | Jan 26, 2001 |
| Mylan | For profit | MKTG | Sep 29, 2017 |
| Novo Nordisk | For profit | MKTG | Jul 2, 2018 |
| PHARMOBEDIENT | For profit | MKTG | Sep 29, 2017 |
| Sandoz | For profit | MKTG | Jun 28, 2018 |
| UBI Pharma Inc. | For profit | MKTG | Oct 1, 2021 |
| Xellia Pharmaceuticals | For profit | MKTG | Jul 2, 2018 |